Fig 1: Quantitative-trait associations between triglycerides, LDL-C, fasting glucose, cholesterol and BMI and the alleles of KLB, FGFR1 and FGF21 were analyzed for all 1688 subjects using multiple linear regression adjusted for sex and age.
Fig 2: Receiver operating characteristic curve analysis of fibroblast growth factor-21 (FGF21) for (A) diabetic retinopathy, area under the curve (AUC)=0.617 (p=0.001), 95% CI 0.581 to 0.652. The optimal cut-off point of serum FGF21 level was 478.76 pg/mL (Youden Index, 0.19; sensitivity, 42.4%; specificity, 76.2%). (B) Sight-threatening diabetic retinopathy, AUC=0.791 (p=0.001), 95% CI 0.746 to 0.836. The optimal cut-off point of serum FGF21 level was 554.69 pg/mL (Youden Index, 0.21; sensitivity, 67.3%; specificity, 84.6%).
Fig 3: Quantitative-trait associations between γ-GT and ALT levels and the alleles of KLB, FGFR1 and FGF21 were analyzed for the 545 NAFLD patients using multiple linear regression adjusted for sex and age.
Fig 4: Quantitative-trait associations between serum FGF21 levels and the alleles of KLB, FGFR1 and FGF21 were analyzed for all 1688 subjects using multiple linear regression adjusted for sex and age.
Fig 5: Characterization of plasma and circulating molecular signaling factors following 12 wks of a multi-ingredient supplement (MIS, green bars) compared to placebo (PLA, pink bars). (A) Post-intervention plasma GDF15 (pg/mL). Post-intervention differences between treatment arms were compared using one-way ANCOVA, implementing the corresponding pre-intervention variables as covariates. Within-group comparisons were made using a paired t-test. (B) Post-intervention plasma FGF21 (pg/mL). (C) Post-intervention plasma IL-6 (pg/mL). (D) Post-intervention plasma leptin (ng/mL). (E) Extracellular vesicle (EV)-associated miRNA species shown as fold change from Day 0 (baseline), n = 15 per group. miRNAs are normalized to exogenous miRNA, cel-miR-54 added prior to RNA isolation. Between-group comparisons were made using the Mann–Whitney U test. Within-group comparisons were made using the non-parametric sign rank test. Asterisks (*) denote significant (p < 0.05) between-group differences versus PLA, p ≥ 0.05, *; p < 0.05. Number signs (#) denote significant within-group differences relative to Day 0 (baseline), #; p < 0.05, ##; p ≤ 0.01. Post-intervention data are presented as adjusted means ± SEs. GDF15, Growth differentiation factor 15; FGF21, fibroblast growth factor 21; IL-6, interleukin 6; miRNA, microRNA.
Supplier Page from Abcam for Human FGF21 ELISA Kit